Hyaluronic Acid in Rheumatology

• Published in: Pharmaceutics Vol. 15; no. 9; p. 2247
• Main Authors: Sprott, Haiko, Fleck, Christian
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30.08.2023; MDPI
• Subjects: Arthritis; Biosynthesis; Cartilage; Cell adhesion & migration; Enzymes; Health aspects; Hyaluronic acid; Hydration; Immune response; Inflammation; joint lubrication; Lubricants & lubrication; Metabolism; Morphogenesis; Osteoarthritis; Pain; Physiological aspects; Physiology; Review; Rheumatic diseases; rheumatoid arthritis; Rheumatology; Shock absorbers; Signal transduction; Viscoelasticity; Viscosity; Wound healing
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15092247

Hyaluronic acid (HA), also known as hyaluronan, is an anionic glycosaminoglycan widely distributed throughout various tissues of the human body. It stands out from other glycosaminoglycans as it lacks sulfation and can attain considerable size: the average human synovial HA molecule weighs about 7 million Dalton (Da), equivalent to roughly 20,000 disaccharide monomers; although some sources report a lower range of 3–4 million Da. In recent years, HA has garnered significant attention in the field of rheumatology due to its involvement in joint lubrication, cartilage maintenance, and modulation of inflammatory and/or immune responses. This review aims to provide a comprehensive overview of HA’s involvement in rheumatology, covering its physiology, pharmacology, therapeutic applications, and potential future directions for enhancing patient outcomes. Nevertheless, the use of HA therapy in rheumatology remains controversial with conflicting evidence regarding its efficacy and safety. In conclusion, HA represents a promising therapeutic option to improve joint function and alleviate inflammation and pain.